UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of:November 2018
Commission file number:001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name into English)
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On November 29, 2018, Therapix Biosciences Ltd. issued a press release entitled “Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture,” a copy of which is attached hereto as Exhibit 99.1.
Exhibits
99.1 | Press Release dated November 29, 2018 |
1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Therapix Biosciences Ltd. | ||
By | /s/ Ascher Shmulewitz, M.D, Ph.D. | |
Name: | Ascher Shmulewitz, M.D, Ph.D. | |
Title: | Chief Executive Officer |
Date: November 29, 2018
2 |